Literature DB >> 24257516

Three-factor model of premorbid adjustment in a sample with chronic schizophrenia and first-episode psychosis.

Ana Barajas1, Judith Usall, Iris Baños, Montserrat Dolz, Victoria Villalta-Gil, Miriam Vilaplana, Jaume Autonell, Bernardo Sánchez, Jorge A Cervilla, Alexandrina Foix, Jordi E Obiols, Josep Maria Haro, Susana Ochoa.   

Abstract

BACKGROUND: The dimensionality of premorbid adjustment (PA) has been a debated issue, with attempts to determine whether PA is a unitary construct or composed of several independent domains characterized by a differential deterioration pattern and specific outcome correlates. AIMS: This study examines the factorial structure of PA, as well as, the course and correlates of its domains.
METHOD: Retrospective study of 84 adult patients experiencing first-episode psychosis (FEP) (n=33) and individuals with schizophrenia (SCH) (n=51). All patients were evaluated with a comprehensive battery of instruments including clinical, functioning and neuropsychological variables. A principal component analysis accompanied by a varimax rotation method was used to examine the factor structure of the PAS-S scale. Paired t tests and Wilcoxon rank tests were used to assess the changes in PAS domains over time. Bivariate correlation analyses were performed to analyse the relationship between PAS factors and clinical, social and cognitive variables.
RESULTS: PA was better explained by three factors (71.65% of the variance): Academic PA, Social PA and Socio-sexual PA. The academic domain showed higher scores of PA from childhood. Social and clinical variables were more strongly related to Social PA and Socio-sexual PA domains, and the Academic PA domain was exclusively associated with cognitive variables.
CONCLUSION: This study supports previous evidence, emphasizing the validity of dividing PA into its sub-components. A differential deterioration pattern and specific correlates were observed in each PA domains, suggesting that impairments in each PA domain might predispose individuals to develop different expressions of psychotic dimensions.
© 2013.

Entities:  

Keywords:  Academic domain; Incipient psychosis; Premorbid functioning; Psychotic disorders; Social domain; Socio-sexual domain

Mesh:

Year:  2013        PMID: 24257516     DOI: 10.1016/j.schres.2013.10.027

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  4 in total

1.  Trajectories of premorbid childhood and adolescent functioning in schizophrenia-spectrum psychoses: A first-episode study.

Authors:  Leslie E Horton; Sarah I Tarbox; Thomas M Olino; Gretchen L Haas
Journal:  Psychiatry Res       Date:  2015-03-02       Impact factor: 3.222

2.  Assessment of Lifespan Functioning Attainment (ALFA) scale: A quantitative interview for self-reported current and functional decline in schizophrenia.

Authors:  Jamie Joseph; William S Kremen; Stephen J Glatt; Carol E Franz; Sharon D Chandler; Xiaohua Liu; Barbara K Johnson; Ming T Tsuang; Elizabeth W Twamley
Journal:  J Psychiatr Res       Date:  2015-04-11       Impact factor: 4.791

3.  Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders.

Authors:  Sherry Kit Wa Chan; Hei Yan Veronica Chan; William G Honer; Tarun Bastiampillai; Yi Nam Suen; Wai Song Yeung; Ming Lam; Wing King Lee; Roger Man King Ng; Christy Lai Ming Hui; Wing Chung Chang; Edwin Ho Ming Lee; Eric Yu Hai Chen
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

4.  Familial and socioeconomic contributions to premorbid functioning in psychosis: Impact on age at onset and treatment response.

Authors:  Alex Hatzimanolis; Pentagiotissa Stefanatou; Emmanouil Kattoulas; Irene Ralli; Stefanos Dimitrakopoulos; Stefania Foteli; Ioannis Kosteletos; Leonidas Mantonakis; Mirjana Selakovic; Rigas-Filippos Soldatos; Ilias Vlachos; Lida-Alkisti Xenaki; Nikolaos Smyrnis; Nicholas C Stefanis
Journal:  Eur Psychiatry       Date:  2020-04-29       Impact factor: 5.361

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.